Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00136942 |
The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Condition | Intervention | Phase |
---|---|---|
Hyperlipidemia |
Drug: Atorvastatin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin |
Estimated Enrollment: | 370 |
Study Start Date: | April 2005 |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Switzerland, BE | |
Pfizer Investigational Site | |
Thun, BE, Switzerland | |
Pfizer Investigational Site | |
Langenthal, BE, Switzerland | |
Switzerland, BL | |
Pfizer Investigational Site | |
Binningen, BL, Switzerland | |
Pfizer Investigational Site | |
Liestal, BL, Switzerland | |
Switzerland, BS | |
Pfizer Investigational Site | |
Basel, BS, Switzerland | |
Pfizer Investigational Site | |
Basel, BS, Switzerland | |
Switzerland, FR | |
Pfizer Investigational Site | |
Duedingen, FR, Switzerland | |
Switzerland, GE | |
Pfizer Investigational Site | |
Onex, GE, Switzerland | |
Pfizer Investigational Site | |
Geneve, GE, Switzerland | |
Switzerland, SZ | |
Pfizer Investigational Site | |
Siebnen, SZ, Switzerland | |
Pfizer Investigational Site | |
Pfaeffikon, SZ, Switzerland | |
Switzerland, TI | |
Pfizer Investigational Site | |
Malvaglia, TI, Switzerland | |
Pfizer Investigational Site | |
Lugano, TI, Switzerland | |
Pfizer Investigational Site | |
Melide, TI, Switzerland | |
Pfizer Investigational Site | |
Vezia, TI, Switzerland | |
Pfizer Investigational Site | |
Lugano, TI, Switzerland | |
Switzerland, VD | |
Pfizer Investigational Site | |
Lausanne, VD, Switzerland | |
Pfizer Investigational Site | |
Prilly, VD, Switzerland | |
Pfizer Investigational Site | |
Ecublens, VD, Switzerland | |
Switzerland, ZG | |
Pfizer Investigational Site | |
Zug, ZG, Switzerland | |
Pfizer Investigational Site | |
Unteraegeri, ZG, Switzerland | |
Switzerland, ZH | |
Pfizer Investigational Site | |
Zuerich, ZH, Switzerland |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A2581089 |
Study First Received: | August 25, 2005 |
Last Updated: | February 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00136942 History of Changes |
Health Authority: | Switzerland: Swissmedic |
Antimetabolites Metabolic Diseases Hyperlipidemias Antilipemic Agents Anticholesteremic Agents |
Hydroxymethylglutaryl-CoA Reductase Inhibitors Metabolic Disorder Atorvastatin Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Hyperlipidemias Metabolic Diseases Molecular Mechanisms of Pharmacological Action Antilipemic Agents Enzyme Inhibitors Anticholesteremic Agents |
Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions Therapeutic Uses Dyslipidemias Atorvastatin Lipid Metabolism Disorders |